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Summary
We performed a comprehensive survey of commonly inactivated tumor suppressor genes in esophageal squamous cell
carcinoma (ESCC) based on functional reactivation of epigenetically silenced tumor suppressor genes by 5-aza-2-deoxycy-
tidine and trichostatin A using microarrays containing 12599 genes. Among 58 genes identified by this approach, 44 (76%)
harbored dense CpG islands in the promoter regions. Thirteen of twenty-two tested gene promoters were methylated in
cell lines, and ten in primary ESCC accompanied by silencing at the mRNA level. Potent growth suppressive activity of
three genes including CRIP-1, Apolipoprotein D, and Neuromedin U in ESCC cells was demonstrated by colony focus
assays. Pharmacologic reversal of epigenetic silencing is a powerful approach for comprehensive identification of tumor
suppressor genes in human cancers.
Introduction In addition to genetic alterations, alterations in DNA methyla-
tion, an epigenetic process present in mammalian cells, are also
Cancer of the esophagus is the eighth most common malig- a hallmark of human cancer (Baylin et al., 2001). The promoter
nancy and ranks as the sixth most frequent cause of death regions of many genes, particularly “housekeeping” genes, are
worldwide (Pissani et al., 1999). The frequency of different histo- populated by many CpG dinucleotides, which are often under-
logic types of esophageal carcinoma varies, but throughout the represented in the remainder of the genome. These regions
world, squamous cell carcinoma is the predominant type. There have been termed “CpG islands,” and, with the exception of
is considerable epidemiological evidence suggesting that alco- genes on the inactive X chromosome and imprinted genes, CpG
hol, tobacco, diets deficient in vitamins/protective antioxidants, islands are protected from methylation in normal cells (Bird,
carcinogens (i.e., frequent consumption of pickled vegetables), 1986; Baylin et al., 2001). This protection is critical since methyl-
ation of CpG islands is associated with loss of expression ofand thermal injuries are important in the pathogenesis of esoph-
ageal squamous cell carcinoma (ESCC) (Chen et al., 1995; Gari- that particular gene. In carcinogenesis, global hypomethylation
(Jones and Laird, 1999; Baylin et al., 2001) is often accompanieddou et al., 1996). Recent advances in molecular biology have
revealed common genetic and/or epigenetic alterations of the by dense hypermethylation of specific promoters (Merlo et al.,
1995; Dammann et al., 2000; Yoshikawa et al., 2001; Li et al.,p53 and p16/Rb tumor suppressor pathways in human ESCC
(Xu et al., 2002; Montesano et al., 1996; Mandard et al., 2000). 2002). Many studies have demonstrated that the silencing of
tumor suppressor genes associated with promoter hypermethy-Further identification of molecular targets would enable the pre-
vention, diagnosis, and treatment of ESCC to be approached lation is a common feature in human cancer, and serves as
an alternative mechanism for loss of tumor suppressor geneat the molecular level. However, as in other cancers, a genome-
wide comprehensive survey of commonly inactivated tumor function. For example, we showed that p16 hypermethylation
is associated with loss of expression and is a common featuresuppressor genes (TSGs) in ESCC has remained elusive.
S I G N I F I C A N C E
Promoter hypermethylation is a common pathway for tumor suppressor gene inactivation. In this study, the authors describe a
method to identify novel methylated genes based on pharmacological unmasking of epigenetic silencing in esophageal cancer
cell lines. This approach and selection algorithm is robust in identifying a number of novel methylated genes in primary esophageal
tumor tissues. These methylated genes provide insight into tumor biology and provide novel diagnostic and therapeutic targets.
Three of these genes showed potent tumor suppressive activity when overexpressed in carcinoma cells.
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Table 1. Genes upregulated by microarray analysis after treatments
KYSE30 KYSE410 KYSE520
1 M 5Aza-dC 46 15 5
1 M 5Aza-dC  300 nM TSA 57 21 51
5 M 5Aza-dC 242 334 149
Unique gene number 289 363 185 Total unique 565 genes
of many solid tumor malignancies (Merlo et al., 1995). Hyper- Results
methylation is associated with inactivation of the tumor suppres-
Pharmacologic unmasking of transcriptionallysor gene VHL and occurs in a subset of clear cell renal cancers
repressed geneswithout inactivating point mutations (Herman et al., 1994; Meyer
We used the demethylating agent 5Aza-dC (1–5 M) for 3 to 5et al., 2000), while hypermethylation-associated loss of p15
days  the deacetylase inhibitor TSA (300 nM last 24 hr) toexpression is a feature of many acute leukemias (Herman et al.,
reactivate genes epigenetically silenced in three esophageal1996). The transcriptional silencing of other tumor suppressor
squamous cell carcinoma (ESCC) cell lines. After treatment, wegenes, such as the mismatch repair gene hMLH1 (Kane et al.,
measured changes in gene expression using microarray chips1997; Herman et al., 1998), has established hypermethylation
containing 12599 transcripts (Affymetrix) and confirmed ran-as a common mechanism for loss of tumor suppressor function
domly picked genes by reverse transcription-polymerase chainin human cancer. Thus, an increasing number of tumor suppres-
reaction (RT-PCR). As expected, treatment with these agentssor genes display both genetic and epigenetic inactivation in
resulted in upregulation (defined as a 3.0-fold increase) of morehuman tumors. Because promoter hypermethylation is linked to
than 500 unique genes (Table 1). Almost all of the genes (80%)
silencing of gene expression, knowledge of methylation patterns
were included in the 5 M 5Aza-dC treatment group, but a few
across the genome, sometimes dubbed “the methylome” (Fein- genes were identified at a lower 5Aza-dC concentration or by
berg, 2001), may help to identify key TSGs inactivated during addition of TSA (see below). We then reasoned that commonly
tumor formation. reactivated genes, inactivated in 2 or 3 ESCC cell lines, were
5-aza-2-deoxycytidine (5Aza-dC) has been used to unravel more likely to represent frequently inactivated TSGs (120 genes).
epigenetic inactivation. 5Aza-dC is incorporated into genomic We further diminished the number of candidate genes by com-
DNA where it forms a covalent complex with methyltransferase paring expression patterns (http://cgap.nci.nih.gov) in normal
active sites (Creusot et al., 1982; Wilson et al., 1983; Jones and esophagus and carcinoma tissue samples (eliminating those
Taylor, 1980). This suicide inhibition depletes methyltransferase genes not expressed in normal tissue) and excluded unknown
activity resulting in generalized demethylation. However, chro- genes. Finally, we focused on 58 genes that were commonly
matin is a complex of DNA and histones, and histone acetylation upregulated after demethylation treatments (Figure 1; Table 2).
also impairs gene transcription (Pennisi, 1997; Marks et al., Fifty-three of the fifty-eight genes (91%) harbored CpG sites
and forty-four genes (76%) harbored dense CpG islands (GC2001); and recently, DNA methylation was demonstrated to help
content  60% or CpG content  15%) in the promoter regionmodel histone acetylation (Gray and Teh, 2001; Eden et al.,
(Table 2). RT-PCR was performed to confirm upregulation after1998). Methyl-CpG binding protein MeCP2 appears to reside
treatment in 25 randomly selected genes (Table 2) in the threein a complex with histone deacetylase activity (Nan et al., 1998),
key ESCC cell lines (Figure 2A). All 25 genes demonstratedwhile DNA methyltransferase binds histone deacetylase 2
robust reexpression after 5 M demethylation treatment. Genes(HDAC2) and a co-repressor, DMAP1 (Rountree et al., 2000).
such as cytokine-like factor-1 (CLF-1) and Hep27 demonstratedThus, densely methylated DNA associates with transcriptionally
synergistic reactivation with 1 M 5Aza-dC  300 nM TSA asrepressive chromatin characterized by the presence of under-
compared to TSA or 5Aza-dC alone in several cancer cellsacetylated histones. Trichostatin A (TSA), a histone deacetylase
(Figure 2B).inhibitor, reverses formation of transcriptionally repressive chro-
matin on methylated promoter templates (Yoshida and Horinou-
Expression and promoter hypermethylationchi, 1999). Epigenetic alterations are thus dynamically linked,
in ESCC cell lines
and synergy between demethylation and histone deacetylase
We then investigated a subset of those 58 genes for silencing
inhibition using TSA was shown to reactivate genes silenced in or downregulation in an additional 12 ESCC cell lines. TE4 and
carcinoma more robustly than 5Aza-dC alone (Cameron et al., TE5 retained expression of Apolipoprotein D (Apo D), while all
1999; Suzuki et al., 2002). the other remaining cell lines were downregulated at the mRNA
In this study, we undertook pharmacological unmasking of level when compared to normal esophagus (Figure 2C). Neu-
ESCC carcinoma cells with 5Aza-dC and TSA followed by cRNA romedin U (NU) was completely silenced in six cell lines, and
microarray analysis to comprehensively identify epigenetically other cell lines also showed a marked reduction in expression
inactivated genes in cancer. This approach identified a large as compared with normal esophagus (Figure 2C). Cystein rich
number of genes with dense promoter hypermethylation. More- intestinal protein 1 (CRIP-1) was completely silenced in 8 out
over, a more closely examined subset of these genes was fre- of 15 ESCC cell lines (53%), while normal esophageal tissues
quently inactivated in primary tumors and displayed clear tumor showed abundant expression of CRIP-1 (Figure 2C). Several
other selected candidate genes (CLF-1, Swiprosin-2, cellularsuppressive activity.
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Figure 1. Flowchart for selection of candidate
TSGs
We used key three ESCC cell lines to screen for
candidate TSGs after 1 to 5 M 5Aza-dC  300
nM TSA treatments followed by cRNA hybridiza-
tion to a 12,599-oligonucleotide microarray. We
obtained over 500 unique genes, which showed
3-fold increase after treatments (Table 1). We
diminished the number of candidates by select-
ing genes commonly upregulated (120) and fur-
ther removed several genes by expression profil-
ing and elimination of unknown genes (58). We
selected 22 genes to test for promoter hyper-
methylation by direct sequence or MSP in ESCC
cell lines and 13 were confirmed. Ten of these
thirteen genes were found to be methylated in
ESCC tissues. Three of these genes were tested
and found to possess growth suppression by a
colony focus assay.
retinol binding protein [CRBP], Metallothionein 1G, Keratin 14, were invariably unmethylated (lysosomal neuraminidase precur-
sor, putative cyclin G1 interacting protein). On the other hand,Crystallin 2, and IL-1 receptor 2) demonstrated considerable
downregulation in ESCC cell lines (Figure 2C). 13 genes (Alpha-tubulin, Swiprosin-2, Insulin-like growth factor
binding protein 2 [IGFBP2], CRBP, Apo D, NU, Claudin-3, Un-In order to confirm promoter hypermethylation in reactivated
genes, we investigated the promoter region of 22 genes (21 coupling protein-2 [UCP-2], CRIP-1, MT 1G, Apolipoprotein CI
[Apo CI], CLF-1, Transglutaminase-2) retained high cytosinegenes harbored dense CpG islands plus Apo D) using bisulfite
sequencing (Table 2). We noted that most candidate genes content in their CpG islands or CpG sites deemed critical for
transcription (Apo D) after bisulfite treatment, indicating heavy(Tbc1d1, lysosomal neuraminidase precursor, Apolipoprotein J
[Apo J], KLF6, putative cyclin G1 interacting protein, and XAP-5) cytosine methylation (Figures 3A and 3B). In all of these genes
except Swiprosin-2, methylation status correlated tightly withwith moderate basal expression before treatment by RT-PCR
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Table 2. Identification of candidates of tumor suppressor genes in esophageal carcinoma
ESCC cell line ESCC tissue
Gene Gene
bank Name Chr. CpGa Unmaskingb expressionc CpGd expressione CpGf known or proposed function
M21302 Small proline rich protein (sprll) 1 (	) * * * UV-induced gene
AI813532 TNF receptor 1B 1p36 () * * * cytokine receptor
AI885852 Histone 2A.2 1q21 () * * * nucleosome protein
J05581 MUC1 1q21 () Yes Yes U tumor antigen
L13463 Regulator of G protein signaling 2 (RGS2) 1q31 () * * U G-protein signal
AF010309 Pig3 2p23 () * * * p53-induced gene
X06956 alpha-tubulin (b alpha 1) 2p36 () * * M 5/5 (100%) 0/10 (0%) microtubule
X59770 IL-1 R2 2q12 (	) Yes Yes * cytokine receptor
AB011103 KIF5C 2q23 (?) Yes * * cytoplasmic transport
X63368 HSP40 homolog (HSJ1) 2q32 () * * * stress-induced gene
W27472 Swiprosin-2 2q36 () Yes Yes M 5/5 (100%) 10/10 (100%) growth arrest?
S37730 IGFBP2 2q36 () * * M 1/5 (20%) 0/10 (0%) IGF signal
M11433 Cellular retinol-binding protein (CRBP) 3q21 () * Yes M 5/5 (100%) 6/10 (60%) retinol-binding protein
J02611 Apolipoprotein D 3q26 () Yes Yes M 3/5 (60%) 8/10 (80%) growth arrest
AB029031 Tbc1d1 4p14 () Yes No * oncosis
AF084481 Transmembrane protein (WFS1) 4p16 () * * * Wolfram syndrome
X76029 Neuromedin U 4q12 () Yes Yes M 3/5 (60%) 3/10 (30%) G-protein receptor ligand
X57522 TAP1 6p21 () * No U tumor antigen processing
AF040958 Lysosomal neuraminidase precursor 6p21 () Yes No U enzyme
X70683 Sry 6p22 () * * * sex-determining gene
AB000714 Claudin-3 7q11 () * * M 4/5 (80%) 6/10 (60%) tight junction
M25915 Apolipoprotein J 8p21 () Yes No * apoptosis
M22488 Bone morphogenic protein 1 (BMP-1) 8p21 () * * U TGF-beta superfamily
AF001461 KLF6 (Zf9) 10p15 () Yes No * tumor suppressor gene
M13755 Interferon-induced 17-kDa/15-kDa 11p36 () * * * Interferon-induced gene
U94592 Uncoupling protein 2 11q13 () Yes Yes M 1/5 (20%) 1/10 (10%) apoptosis
W68521 Cystatin E/M (6) 11q13 () * * * protease inhibitor
AF001436 Cdc42 effector protein 2 (CEP2) 11q13 () * * * motility inhibition
X15675 pTR7 11q13 () * * * repetitive sequence gene
AL038340 Crystallin alpha B 11q22 () Yes Yes * stress-induced gene
AJ001684 NKG2C 12p13 (	) * * * NK cell recognition
AJ001685 NKG2E 12p13 (	) Yes * * NK cell recognition
M20681 GLUT3 12p13 () * * * glucose transport
U31875 Hep27 14q11 () Yes * * growh arrest?
X81637 Clathrin light chain b 14q21 () * * * membrane recycling
X67325 Interferon stimulatory gene 12 (p27) 14q32 () Yes * * IFN-induced gene
AI017574 Cystein rich protein with LIM (CRIP1) 14q32 () Yes Yes M 1/5 (20%) 2/10 (20%) LIM protein
AI985272 Neuromedin B 15q22 () * * * G-protein receptor ligand
NM_002201 HEM45 (interferon stimulatory gene 20) 15q26 () Yes * * IFN-induced gene
J03910 Metallothionein-1G 16q () * Yes M 5/5 (100%) 4/10 (40%) apoptosis-related gene
NM_004165 Rad 16q22 () Yes Yes U motility inhibition
AA976838 Apolipoprotein CI 16q22 () * * M 3/5 (60%) 8/10 (80%) growth promotion?
J00124 Keratin 14 17q12 () Yes * * intermediate filament
U20982 IGFBP4 17q12 () Yes * * IGF signal
Z19574 Cytokeratin 17 17q12 () * * * intermediate filament
AF059293 Cytokine-like factor-1 (CLF-1) 19p13 () Yes Yes M 3/5 (60%) 5/10 (50%) cytokine receptor homolog
D12620 Cytochrome P-450LTBV 19p13 () * * * electron transmission
AF061812 Keratin 16 19q12 () * * * intermediate filament
U76702 Follistatin-related protein FLRG 19q13 () Yes * U TGF-beta related gene
AF044968 Nectin 2 19q13 () * * * tight junction
AA1524 06 “Cytochrome oxidase c, type VIIa” 19q13 () * * * electron transmission
M37457 “Na, K-ATPase catalytic subunit, alpha-III” 19q13 () * * * ion transport
U61837 Putative cyclin G1 interacting protein 20p13 () Yes No U cell cycle (G2/M)
M55153 Transglutaminase 2 (tissue glutaminase) 20q11 () Yes Yes M 3/5 (60%) 4/10 (40%) apoptosis
W72816 Cleavage stimulation factor 20q13 () * * U BRCA1-related gene
X75315 Seb4B (RPM type RNA binding protein) 20q13 () * * * RNA binding protein
X91817 Transketorase 2 Xq28 () * * * metabolite cofactor
AD001530 XAP-5 Xq28 () Yes No * repetitive sequence gene
a CpG sites. () dense CpG islands, () CpG sites, (	) no CpG sites in the promoter region.
b RT-PCR results of the experiment after treatments. *: not done. Yes: confirmed silencing in three key cells and reactivation after treatments.
c Gene expression by RT-PCR in extended panel of ESCC cells. *: not done. Yes: silencing confirmed in several cell lines. No: ubiquitously expressed in all
investigated cell lines.
d CpG status of ESCC cells. M: methylated, U: unmethylated, *: not done.
e Gene expression by RT-PCR in ESCC tissues. Silenced tumors/tumors tested (% silenced).
f Promoter methylation by direct sequence in ESCC tissues. Methylated tumors/tumors tested (% in methylation).
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Figure 2. Genes silenced in carcinoma cell lines
(KYSE30, KYSE410, and KYSE520) and reactivated
by 5Aza-dC and/or TSA treatments
A: Five and/or 1 M 5Aza-dC treatment reacti-
vated genes identified by microarray hybridiza-
tion and selected by the algorithm in Figure 1.
GAPDH expression was used for equal loading
into each lane. a: 5Aza-dC in solution of acetic
acid/PBS. m: mock including the same volume
of acetic acid.
B: One M 5Aza-dC and 300 nM TSA treatment
showed synergistic reactivation of several genes
(CLF-1 and Hep27). Treatment with both showed
more potent induction than 5Aza-dC or TSA
alone. TA: Trichostatin A aza: 5Aza-dC.
C: Gene expression of Apo D and other genes
listed on the left in ESCC cell lines. ESCC cell lines
showed marked reduction in expression of these
genes compared to robust expression in normal
esophagus (right). GAPDH expression is shown as
a loading control at the bottom.
expression status. For example, KYSE30 was silenced for NU level. For Swisprosin-2, methylation did not correlate with de-
creased expression in primary tumors or cell lines (Table 2). Aexpression and harbored dense methylation of the promoter,
while KYSE410 and KYSE520 both expressed NU and were few tumors did not harbor methylation, but still demonstrated
occasional downregulation of a particular gene (Table 2), pre-free of promoter methylation (Figure 3A). For Apo D, all ESCC
cell lines except TE5 demonstrated methylation of the promoter, sumably due to other mechanisms.
while TE5, which expressed Apo D abundantly, did not harbor
any methylation (Figure 3A). TE2, TE4, and TE13 showed weak Tumor suppressor activity
expression of Apo D mRNA (Figure 2C) and approximately 50% We then focused on three methylated genes and their ability to
of the cells harbored unmethylated alleles by direct sequence function as suppressors of tumor growth (CRIP-1, Apo D, and
of bisulfite-treated DNA (data not shown). NU) in KYSE30, which was silenced for all three genes. We
tested these three genes by a colony focus assay using G418
Expression and promoter hypermethylation selection after transfection with each gene or control vector
in primary ESCC tumors (pcDNA3). STAT3 is an oncogenic protein and STAT3C is a
We then investigated these 13 methylated genes for promoter constitutive active form (Bromberg et al., 1999). STAT3 expres-
methylation in ESCC tissues by MSP or direct sequence analysis sion did not change after 5Aza-dC treatments, and thus it was
(Figure 3C). Ten of the thirteen genes harbored tumor-specific used as a negative control of tumor suppressive activity. In the
promoter methylation (Figure 4A). The frequency of tumor meth- case of NU, we used the actual protein at a concentration of 100
ylation ranged from 10% (UCP-2) to 80% (Apo C1). Apo D M. All three genes demonstrated potent tumor-suppressing
was methylated in almost all primary ESCC tissues (80%), and activity with a marked reduction of colony forming ability after
showed low-level methylation in some normal tissues by MSP transfection (Apo D: 61.3%  15.0%, CRIP-1: 18.3%  15.7%)
(Figure 4B). Swiprosin-2 and Alpha-tubulin showed methylation or addition of protein (NU: 33.6% 12.3%) in three independent
in normal esophageal mucosa specimens, suggesting tissue- experiments (Figures 5A–5C). To further confirm a role for
specific, but not tumor-specific, hypermethylation (data not CRIP-1 in expression, we transiently transfected IRES-CRIP-1
shown). None of the 10 primary tumors tested harbored IGFBP2 into KYSE30 cells. Cells expressing high GFP protein (and thus
methylation (data not shown). CRIP-1 simultaneously) showed classic morphological changes
We then investigated expression of these 13 genes in five of apoptosis including rounding, apoptotic body appearance,
primary ESCC tissues and found them to be reduced in expres- and nuclear shrinkage. A TUNEL assay (Figure 5D) confirmed
sion in the primary cancers compared to the corresponding DNA fragmentation in CRIP-1-expressing cells.
normal tissues (Table 2 and Figure 4C). NU and Apo D were
markedly repressed at the mRNA level in several primary tumors Discussion
as compared to the corresponding normal tissues (Figure 4C).
Every gene (except Swisprosin-2) methylated in primary tumors Pharmacologic reversal of epigenetic silencing uncovered a
myriad of transcriptionally repressed genes in ESCC. We identi-demonstrated a marked decrease in expression at the RNA
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Figure 3. Promoter methylation of representative
candidate suppressor genes
A: Direct sequence of NU and Apo D promoters.
All guanines present after sequencing are de-
rived from methyl cytosines on the comple-
mentary strand. In cell lines that showed marked
reduction of expression, expression levels corre-
lated tightly with methylation status.
B: Bisulfite direct sequencing of the gene promot-
ers in representative ESCC cell lines. CRBP
(KYSE30), CRIP-1 (KYSE410), MT 1G (KYSE30), CLF-1
(KYSE30), Claudin-3 (KYSE30), and UCP-2
(KYSE30).
C: Representative cases of methylation for NU,
CLF-1, CRIP-1, and Claudin-3 in primary ESCC as
compared to normal esophageal tissues. Normal
tissues were obtained from normal distal mucosa
in patients with ESCC.
fied several unknown TSG candidates, using a cutoff of a 3-fold reexpression in a higher number of cells, facilitating our direct
hybridization approaches. Multiple approaches to reverse epi-increase by microarray analysis and an intuitive algorithm. The
majority of genes were identified by high dose 5Aza-dC treat- genetic silencing are likely to yield the most comprehensive
gene surveys. It is likely that other algorithms and better demeth-ment, but a subset of genes were reactivated by synergistic
treatment with low dose 5Aza-dC and TSA as demonstrated ylation or HDAC inhibition could also improve the yield by further
unmasking of methylated targets.previously in colon cancer cell lines (Cameron et al., 1999; Su-
zuki et al., 2002). This survey may represent a minimal number NU is proposed to be involved in normal esophageal mucosa
integrity, and NU as well as the recently identified cognate re-of upregulated genes since reversal of epigenetic silencing is
likely to occur in a subset of cells with variable reexpression ceptor (Hedrick et al., 2000) are abundantly expressed in normal
esophageal mucosa (Hedrick et al., 2000; Lynch et al., 2000)(Cameron et al., 1999). A more complex approach involving
selective cloning identified many methylated targets in colo- (Figure 4C). The NU receptor (FM3) is a G protein-coupled recep-
tor that can signal through PI3 kinase 
, recently confirmed torectal cancer and could be used to identify more subtle targets
(Suzuki et al., 2002). Our use of high dose 5Aza-dC likely induced block growth of human colon cancer cells (Sasaki et al., 2000).
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Figure 4. Methylation and expression in primary
tumors
A: Methylation in primary tumors for 13 tested
genes that showed methylation in ESCC cell
lines. Green boxes indicate methylation of the
promoter region. Light speckled green indicates
partial (low-level) methylation by direct se-
quencing. T: Tumor tissues, N: normal esophageal
mucosa.
B: MSP analysis of ESCC tissue samples for Apo D.
Representative cases of tumor (T) and corre-
sponding normal esophageal mucosa (N) in pri-
mary tumors. Low-level methylation in some dis-
tal normal tissues is seen.
C: Representative gene expression in ESCC tu-
mor tissues by RT-PCR. NU and Apo D in tumors
(T) showed marked reduction in expression as
compared to normal mucosa (N). The low-level
or minimal expression in tumors is probably due
to normal cell contamination in the primary tissue
samples. GAPDH expression is shown as a load-
ing control.
Moreover, in our present study, the list of candidate TSGs in- partner, implicating CRIP-1 in NF-kappa B and JNK pathways
critical for apoptosis (Wang et al., 2001).cludes Neuromedin B and RSG2, which are thought to be in-
volved on the same pathway. Apo D is well known to be associated with cell growth arrest
(Do Carmo et al., 2002), but its underlying mechanism is un-CRIP-1 has a LIM domain (Tsui et al., 1994) recently con-
firmed to be involved in carcinogenesis (e.g., Lmo2 and Lmo4). known. Other apolipoproteins (Apo CI and Apo J) are also in-
cluded in our list of 58 genes. Apo J was also demonstrated toLmo2 is a transcriptional factor proposed to play an oncogenic
role in T cell leukemogenesis (Grutz et al., 1998), perhaps by possess a potent ability to induce cell death (Han et al., 2001).
Recently, Apo D was demonstrated to bind to a cytokine typeenhancing angiogenesis (Yamada et al., 2002). Lmo4 is over-
expressed in breast cancer cells and binds with BRCA1, resulting receptor that mediates MAP kinase signaling (Liu et al., 2001).
This cytokine signaling pathway may also be used by recognizedin suppression of BRCA1 transcriptional activity (Visvander et
al., 2001; Sum et al., 2002). Paxillin is a focal adhesion-associ- tumor suppressors like SOCS-1 (Yoshikawa et al., 2001), and
our study suggests that the IL-1 receptor antagonist (IL-1 R2)ated adaptor protein with multiple LIM domains involved in cell
spreading and motility (Schaller, 2001). Paxillin LIM binds with (Colotta et al., 1993) and CLF-1 (Elson et al., 1998) may also
be involved.-tubulin (Herreros et al., 2000), a known partner for other critical
tumor suppressors including APC and Fhit. Our identified LIM The chromosomal localization of the 58 candidate genes is
listed in Table 2. We found that many TSGs candidates weregene (CRIP-1) is a very small molecule (open reading frame is
273 bp) that could modulate other LIM proteins in a dominant- clustered in specific chromosomal regions (Table 2), suggesting
the presence of methylated chromosomal regions with highlynegative manner and potentially modulate or affect many path-
ways in carcinogenesis. Moreover, our yeast two-hybrid screen dense methylation and reduced gene expression in tumors that
can be unmasked after pharmacological demethylation treat-(D.S. and K.Y., unpublished data) identified Ubc13 as a binding
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Figure 5. Colony focus assay in KYSE30
All results are an average of three independent
experiments.
A: Colony formation after 2 week selection of
G418 with pcDNA3 (mock), pcDNA3-Apo D (Apo
D), pcDNA3-CRIP-1 (CRIP-1), pcDNA3-p53 (p53),
and pcDNA3-stat3C (stat3C).
B: Colony formation efficiency of each gene of
stat3C (2), Apo D (3), CRIP-1 (4), and p53 (5) as
compared to mock (1). Mock colony number is
arbitrarily set at 100% colony formation with Apo
D at 61% and 18% for CRIP-1.
C: Colony formation after 2 week selection with
G418 using pcDNA3 (mock) with PBS or NU (final
concentration, 100 M). Colony formation effi-
ciency is markedly reduced after NU treatment
(43%).
D: Upper box indicates concomitant IRES-GFP
and CRIP-1 expression. These cells showed mor-
phological evidence of apoptosis with rounding,
apoptotic body appearance, and nuclear
shrinkage. The lower box shows the merged im-
age of rhodamine-TUNEL and Hoechst staining
of the nucleus. Only CRIP-1-transfected cells
demonstrated apoptosis (red color), while cells
transformed with IRES alone showed no alter-
ations (data not shown).
ment. Apo D, NU, and CRIP-1 are localized at 3q26, 4q12, and silenced suppressor genes. Complementary genomic array ap-
proaches that search for methylated CpG islands can be com-14q24, respectively. All of these loci have been shown to harbor
chromosomal deletions or LOH in various cancer (Kruzelock et pared to functional reactivation surveys (Gitan et al., 2002; Ador-
jan et al., 2002; Shi et al., 2002). Genes that harbor CpG islandsal., 1997; Burger et al., 1998; Wo et al., 2000; Simon et al.,
1995; Herbers et al., 1997) and 3q26 has been reported as in the promoter regions and methylation in tumor tissue are
likely to be bonafide TSGs (Table 2). Our approach thus yieldeda fragile site (Murano et al., 1989). We identified ten genes
methylated in a tumor-specific pattern, but, whether methylated three new TSG’s and many more remain to be explored. It is
clear, however, that not all genes identified by this approachor not, all of these genes remain candidates in TSG pathways.
MUC2 was identified in our survey and knockout mice, for exam- are upregulated due to promoter demethylation. Such genes
still provide important insights into biologic mechanisms eluci-ple, were recently shown to be predisposed to tumor formation
(Velcich et al., 2002). It is likely that many genes in our survey dated by activating gene promoters upstream in a given
pathway.represent TSGs candidates that have not been previously tested
for genetic or epigenetic inactivation in cancers. The use of MSP allows rapid detection of the frequency of
inactivation in primary tumors by methylation, while functionalWe have identified candidate genes and pathways epigenet-
ically regulated in ESCC using functional reversal of methylation analysis allows rapid assessment of suppressor activity. These
identified genes will further contribute to our understanding ofand deacetylation followed by hybridization on microarrays. This
approach is rapid, robust, and can be easily repeated in other the biologic progression of ESCC and thus represent important
therapeutic targets. Moreover, the rapid development of MSPcancer cell lines to comprehensively search for epigenetically
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Construction of human expression vectorsassays after gene identification allows robust analysis of primary
A full-length CRIP-1 cDNA was isolated from TE2 using PCR with the primertumors and other clinical samples for implementation of promis-
sets 5-CAGAAGCTTCCACCATGCCCAAGTGTCCCAAGTGC-3 and 5-ing molecular detection approaches (Esteller et al., 1999; Kawa-
CTCTCGGTGTGAAAGTTCATTAGATCTGAC-3. The PCR product with
kami et al., 2000; Sanchez-Cespedes et al., 2000; Jeronimo et HindIII and XbaI was cut out from a gel and ligated to HindIII-XbaI digested
al., 2001; Usadel et al., 2002). pcDNA3 (Invitrogen), which harbors a CMV promoter. One clone, pcDNA3-
CRIP-1, harbored an insertion with a sense orientation and a correct se-
Experimental procedures quence. p53 was amplified as a template of pRCC-p53 (Osada et al., 1998),
subcloned into pcDNA3 in HindIII and Xba sites, and then sequenced. Dr.
Cell lines and tissue samples Gregor, Department of Molecular Biology at The Scripps Research Institute
ESCC lines TE1, TE2, TE3, TE4, TE5, TE7, TE13, KYSE30, KYSE70, kindly provided Apo D cDNA inserted into pcDNA3. Dr. Darnell from the
KYSE110, KYSE140, KYSE150, KYSE200, KYSE410, and KYSE520 were Department of Oncology of the University of Rockefeller kindly provided
obtained from the Cell Response Center for Biomedical Research Institute STAT3C cDNA inserted into pcDNA3 (Bromberg et al., 1999).
of Department, Aging and Cancer, Tohoku University (TE series) and kindly
provided by Dr. Shimada in the Department of Surgery, Kyoto University Transfection and colony formation assay
(KYSE series). Cell lines were grown in RPMI1640 supplemented with 10% Colony formation assays were performed in monolayer culture (Yoshikawa
fetal bovine serum for isolation of DNA and RNA. Primary ESCC tumors and et al., 2001). Cells were plated at 2  104 per well using 6-well plates, and
corresponding adjacent normal tissues were obtained from the Gastroenter- transfected with either pcDNA3-p53, pcDNA3-STAT3C, pcDNA3-CRIP-1,
ology Division, the Department of Medicine, and the University of Maryland pcDNA3-Apo D, or no insert of pcDNA3-mock (1 g) using Lipofectamine
School of Medicine. Plus reagents (Invitrogen) according to the manufacturer’s protocol. The
cells were then detached and plated on 100 mm tissue culture dishes at
5Aza-dC and TSA treatment of cells 24 to 48 hr post-transfection, and simultaneously harvested at 48 hr after
Cells were split to low density (5  105 per T-25 flask) 12–24 hr before transfection to confirm their expression at the mRNA level (RT-PCR) for
treatment. Cells were then treated for 3, 4, or 5 days with 1 or 5 M 5Aza- Apo D. Cells transfected with CRIP-1 died rapidly by 48 hr after transfection,
dC (Sigma) from 100 mM 50% acetic acid dissolved stock or were mock- and thus mRNA levels were evaluated 24 hr after transfection. Apo D and
treated with the same volume of phosphate-buffered saline (PBS) including CRIP-1 RNA levels in the cells were between 1.5-fold and 2.0-fold higher
the same acetic acid. Following an initial incubation (48 hr) of 5Aza-dC, a
than basal expression of unmethylated cell lines. Cells were selected with
final concentration of 300 nM TSA (Sigma) was added to the media from a
G418 (1 mg/ml), and colonies were counted 2 weeks after transfection.
5 mM ethanol dissolved stock or cells were mock-treated with an identical
For treatment with NU (Phoenix Pharmaceutical), the colony focus assay
volume of ethanol.
included 100 M NU in control PBS or the medium.
Microarray and RT-PCR analysis
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